Header Logo

Connection

JOSEPH JANKOVIC to Aged

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Aged.
JOSEPH JANKOVIC
Connection Strength
3.580
Aged
  1. Functional Head Tremor: Contrasting Features with Other Tremor Etiologies. Mov Disord Clin Pract. 2025 Dec; 12(12):2289-2295.
    View in: PubMed
    Score: 0.064
  2. Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis. Toxicon. 2024 Sep; 248:108035.
    View in: PubMed
    Score: 0.060
  3. Functional Neurological Disorders Among Patients With Tremor. J Neuropsychiatry Clin Neurosci. 2025; 37(1):61-66.
    View in: PubMed
    Score: 0.060
  4. Medication refractory restless legs syndrome: Real-world experience. J Neurol Sci. 2024 Aug 15; 463:123121.
    View in: PubMed
    Score: 0.060
  5. Leg stereotypy syndrome: phenomenological and quantitative analysis. J Neurol. 2024 Aug; 271(8):5519-5524.
    View in: PubMed
    Score: 0.060
  6. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
    View in: PubMed
    Score: 0.041
  7. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 10 01; 75(10):1206-1214.
    View in: PubMed
    Score: 0.040
  8. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018 07 19; 10(7).
    View in: PubMed
    Score: 0.040
  9. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.039
  10. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017 May 15; 376:129-132.
    View in: PubMed
    Score: 0.036
  11. Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017 Jan 15; 372:57-59.
    View in: PubMed
    Score: 0.035
  12. Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord. 2017 03; 32(3):433-440.
    View in: PubMed
    Score: 0.035
  13. Psychogenic Ophthalmologic Movement Disorders. J Neuropsychiatry Clin Neurosci. 2016; 28(3):195-8.
    View in: PubMed
    Score: 0.033
  14. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna). 2015 Nov; 122(11):1515-21.
    View in: PubMed
    Score: 0.032
  15. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
    View in: PubMed
    Score: 0.031
  16. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 Dec; 20(12):1345-51.
    View in: PubMed
    Score: 0.030
  17. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014 Nov; 90:344-8.
    View in: PubMed
    Score: 0.030
  18. The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):573-5.
    View in: PubMed
    Score: 0.029
  19. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan; 29(1):126-30.
    View in: PubMed
    Score: 0.029
  20. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013 Aug; 24(2):298-306.
    View in: PubMed
    Score: 0.028
  21. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013 Oct; 28(12):1748-9.
    View in: PubMed
    Score: 0.028
  22. Respiratory disorders associated with dystonia. Mov Disord. 2012 Dec; 27(14):1816-9.
    View in: PubMed
    Score: 0.027
  23. Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord. 2012 Aug; 18(7):859-63.
    View in: PubMed
    Score: 0.026
  24. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun; 18(5):488-93.
    View in: PubMed
    Score: 0.025
  25. Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012 Feb; 83(2):202-4.
    View in: PubMed
    Score: 0.025
  26. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011 Sep; 17(8):625-8.
    View in: PubMed
    Score: 0.025
  27. Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med. 2011 Sep; 123(5):116-21.
    View in: PubMed
    Score: 0.025
  28. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
    View in: PubMed
    Score: 0.024
  29. Parkinsonism and dystonia associated with adalimumab. Mov Disord. 2011 Jul; 26(8):1556-8.
    View in: PubMed
    Score: 0.024
  30. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene. Mov Disord. 2011 Apr; 26(5):925-7.
    View in: PubMed
    Score: 0.024
  31. Asian over-representation among patients with hemifacial spasm compared to patients with cranial-cervical dystonia. J Neurol Sci. 2010 Nov 15; 298(1-2):61-3.
    View in: PubMed
    Score: 0.023
  32. Tourette's syndrome in adults. Mov Disord. 2010 Oct 15; 25(13):2171-5.
    View in: PubMed
    Score: 0.023
  33. Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord. 2010 Sep 15; 25(12):1938-43.
    View in: PubMed
    Score: 0.023
  34. Examination of the MASH1 gene in patients with Parkinson's disease. Biochem Biophys Res Commun. 2010 Feb 19; 392(4):548-50.
    View in: PubMed
    Score: 0.022
  35. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
    View in: PubMed
    Score: 0.022
  36. Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease. Neurosci Lett. 2010 Jan 14; 468(3):195-7.
    View in: PubMed
    Score: 0.022
  37. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009 Dec 15; 287(1-2):159-71.
    View in: PubMed
    Score: 0.022
  38. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 Mar; 81(3):315-9.
    View in: PubMed
    Score: 0.021
  39. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
    View in: PubMed
    Score: 0.021
  40. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009 Dec; 15(10):758-61.
    View in: PubMed
    Score: 0.021
  41. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009 Sep 15; 284(1-2):177-8.
    View in: PubMed
    Score: 0.021
  42. Acquired hepatocerebral degeneration. J Neurol. 2009 Mar; 256(3):320-32.
    View in: PubMed
    Score: 0.021
  43. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009 Feb 15; 24(3):407-13.
    View in: PubMed
    Score: 0.021
  44. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009; 11(5):293-307.
    View in: PubMed
    Score: 0.020
  45. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008 Dec 15; 23(16):2307-11.
    View in: PubMed
    Score: 0.020
  46. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008 Aug; 14(4):253-4.
    View in: PubMed
    Score: 0.020
  47. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008 May-Jun; 31(3):127-33.
    View in: PubMed
    Score: 0.020
  48. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord. 2008 Mar 15; 23(4):616-9.
    View in: PubMed
    Score: 0.019
  49. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008 Mar; 14(2):89-99.
    View in: PubMed
    Score: 0.019
  50. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008 Mar; 48(3):379-84.
    View in: PubMed
    Score: 0.019
  51. Tardive gait. Clin Neurol Neurosurg. 2008 Feb; 110(2):198-201.
    View in: PubMed
    Score: 0.019
  52. Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report. J Neurosurg. 2007 Nov; 107(5):1036-8.
    View in: PubMed
    Score: 0.019
  53. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008 Jul; 79(7):789-95.
    View in: PubMed
    Score: 0.019
  54. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):256-65.
    View in: PubMed
    Score: 0.019
  55. The other Babinski sign in hemifacial spasm. Neurology. 2007 Jul 24; 69(4):402-4.
    View in: PubMed
    Score: 0.019
  56. Hereditary chin tremor in Parkinson's disease. Clin Neurol Neurosurg. 2007 Nov; 109(9):784-5.
    View in: PubMed
    Score: 0.018
  57. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007 Dec 15; 263(1-2):94-9.
    View in: PubMed
    Score: 0.018
  58. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007 Sep 15; 260(1-2):199-203.
    View in: PubMed
    Score: 0.018
  59. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007 May; 64(5):676-82.
    View in: PubMed
    Score: 0.018
  60. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007 May 29; 419(2):104-7.
    View in: PubMed
    Score: 0.018
  61. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr; 106(4):621-5.
    View in: PubMed
    Score: 0.018
  62. Genetics of essential tremor. Brain. 2007 Jun; 130(Pt 6):1456-64.
    View in: PubMed
    Score: 0.018
  63. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007 Jan; 22(1):10-3.
    View in: PubMed
    Score: 0.018
  64. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007 Jan 31; 252(2):113-20.
    View in: PubMed
    Score: 0.018
  65. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006 Dec 21; 251(1-2):102-6.
    View in: PubMed
    Score: 0.018
  66. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006 Oct 23; 407(2):97-100.
    View in: PubMed
    Score: 0.017
  67. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006 Aug; 21(8):1252-4.
    View in: PubMed
    Score: 0.017
  68. Psychogenic tremor: long-term outcome. CNS Spectr. 2006 Jul; 11(7):501-8.
    View in: PubMed
    Score: 0.017
  69. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006 Jul 11; 103(28):10753-8.
    View in: PubMed
    Score: 0.017
  70. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Sep; 12(6):382-7.
    View in: PubMed
    Score: 0.017
  71. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006 Apr; 104(4):506-12.
    View in: PubMed
    Score: 0.017
  72. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006 Jun 19; 401(1-2):16-9.
    View in: PubMed
    Score: 0.017
  73. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006 Feb; 63(2):273-7.
    View in: PubMed
    Score: 0.017
  74. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1636-9.
    View in: PubMed
    Score: 0.017
  75. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005 Sep 13; 65(5):765-7.
    View in: PubMed
    Score: 0.016
  76. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005 Aug 23; 65(4):651-2.
    View in: PubMed
    Score: 0.016
  77. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005 Aug 09; 65(3):355-9.
    View in: PubMed
    Score: 0.016
  78. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005 Aug; 62(8):1290-5.
    View in: PubMed
    Score: 0.016
  79. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005 Jun; 57(6):933-4.
    View in: PubMed
    Score: 0.016
  80. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005 May; 20(5):592-7.
    View in: PubMed
    Score: 0.016
  81. Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm. Parkinsonism Relat Disord. 2025 Feb; 131:107241.
    View in: PubMed
    Score: 0.015
  82. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004 Nov-Dec; 27(6):274-7.
    View in: PubMed
    Score: 0.015
  83. Premutation alleles associated with Parkinson disease and essential tremor. JAMA. 2004 Oct 13; 292(14):1685-6.
    View in: PubMed
    Score: 0.015
  84. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004 Sep 28; 63(6):1096-8.
    View in: PubMed
    Score: 0.015
  85. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004 Jun; 19(6):692-5.
    View in: PubMed
    Score: 0.015
  86. Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: a possible complication of chronic hypoxia and carbon monoxide toxicity? Mov Disord. 2004 Apr; 19(4):465-9.
    View in: PubMed
    Score: 0.015
  87. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
    View in: PubMed
    Score: 0.015
  88. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004; 94:29-36.
    View in: PubMed
    Score: 0.014
  89. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004 Jan; 19(1):36-42.
    View in: PubMed
    Score: 0.014
  90. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003 Nov; 60(11):1595-8.
    View in: PubMed
    Score: 0.014
  91. Hearing impairment in essential tremor. Neurology. 2003 Oct 28; 61(8):1093-7.
    View in: PubMed
    Score: 0.014
  92. COVID19-associated new-onset movement disorders: a follow-up study. J Neurol. 2023 May; 270(5):2409-2415.
    View in: PubMed
    Score: 0.014
  93. Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003 Feb; 114(2):288-94.
    View in: PubMed
    Score: 0.014
  94. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002 Nov-Dec; 25(6):300-2.
    View in: PubMed
    Score: 0.013
  95. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002 Sep; 17(5):1031-5.
    View in: PubMed
    Score: 0.013
  96. Secondary paroxysmal dyskinesias. Mov Disord. 2002 Jul; 17(4):726-34.
    View in: PubMed
    Score: 0.013
  97. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002 Jun; 19(3):245-51.
    View in: PubMed
    Score: 0.013
  98. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002 Mar; 59(3):421-4.
    View in: PubMed
    Score: 0.013
  99. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
    View in: PubMed
    Score: 0.013
  100. Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis. JAMA Neurol. 2022 02 01; 79(2):185-193.
    View in: PubMed
    Score: 0.013
  101. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002 Jan; 19(1):67-72.
    View in: PubMed
    Score: 0.013
  102. Secondary causes of paroxysmal dyskinesia. Adv Neurol. 2002; 89:401-20.
    View in: PubMed
    Score: 0.013
  103. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001 Oct 23; 57(8):1392-6.
    View in: PubMed
    Score: 0.012
  104. Functional decline in Parkinson disease. Arch Neurol. 2001 Oct; 58(10):1611-5.
    View in: PubMed
    Score: 0.012
  105. Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach. Parkinsonism Relat Disord. 2021 06; 87:124-129.
    View in: PubMed
    Score: 0.012
  106. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001 Mar; 48(3):535-41; discussion 541-3.
    View in: PubMed
    Score: 0.012
  107. Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
    View in: PubMed
    Score: 0.012
  108. Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. Parkinsonism Relat Disord. 2021 03; 84:105-111.
    View in: PubMed
    Score: 0.012
  109. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm (Vienna). 2001; 108(1):63-70.
    View in: PubMed
    Score: 0.012
  110. Effects of pallidotomy on gait and balance. Adv Neurol. 2001; 87:271-81.
    View in: PubMed
    Score: 0.012
  111. Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574.
    View in: PubMed
    Score: 0.012
  112. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000 Oct; 57(10):1464-9.
    View in: PubMed
    Score: 0.012
  113. Botulinum toxin in the treatment of tics. Arch Neurol. 2000 Aug; 57(8):1190-3.
    View in: PubMed
    Score: 0.011
  114. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020 09; 78:56-60.
    View in: PubMed
    Score: 0.011
  115. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000 Jul; 15(4):678-82.
    View in: PubMed
    Score: 0.011
  116. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000 Mar; 57(3):369-72.
    View in: PubMed
    Score: 0.011
  117. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
    View in: PubMed
    Score: 0.011
  118. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb; 131(2):211-6.
    View in: PubMed
    Score: 0.011
  119. Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
    View in: PubMed
    Score: 0.011
  120. Essential tremor: clinical characteristics. Neurology. 2000; 54(11 Suppl 4):S21-5.
    View in: PubMed
    Score: 0.011
  121. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
    View in: PubMed
    Score: 0.011
  122. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999 Dec 10; 53(9):2102-7.
    View in: PubMed
    Score: 0.011
  123. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999 Nov; 67(5):646-50.
    View in: PubMed
    Score: 0.011
  124. Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019 09; 66:166-170.
    View in: PubMed
    Score: 0.011
  125. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999 Aug; 156(8):1279-81.
    View in: PubMed
    Score: 0.011
  126. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999 Aug 01; 167(1):62-7.
    View in: PubMed
    Score: 0.011
  127. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999 Jul; 17(3):196-201.
    View in: PubMed
    Score: 0.011
  128. Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc. 1999 Jun; 31(6):761-6.
    View in: PubMed
    Score: 0.011
  129. Head tremor at disease onset: an ataxic phenotype of cervical dystonia. J Neurol. 2019 Aug; 266(8):1844-1851.
    View in: PubMed
    Score: 0.010
  130. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
    View in: PubMed
    Score: 0.010
  131. Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord. 1999 Mar; 14(2):345-9.
    View in: PubMed
    Score: 0.010
  132. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999 Jan; 14(1):57-62.
    View in: PubMed
    Score: 0.010
  133. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999 Jan; 56(1):98-102.
    View in: PubMed
    Score: 0.010
  134. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):1-4.
    View in: PubMed
    Score: 0.010
  135. Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999; 11(2):259-67.
    View in: PubMed
    Score: 0.010
  136. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998 Dec; 21(12):1740-7.
    View in: PubMed
    Score: 0.010
  137. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998 Nov; 65(5):722-8.
    View in: PubMed
    Score: 0.010
  138. Predictors of alcohol responsiveness in dystonia. Neurology. 2018 11 20; 91(21):e2020-e2026.
    View in: PubMed
    Score: 0.010
  139. Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Parkinsonism Relat Disord. 2019 03; 60:126-132.
    View in: PubMed
    Score: 0.010
  140. Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8567-E8576.
    View in: PubMed
    Score: 0.010
  141. Consensus for the measurement of the camptocormia angle in the standing patient. Parkinsonism Relat Disord. 2018 07; 52:1-5.
    View in: PubMed
    Score: 0.010
  142. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998 Jun; 50(6):1624-9.
    View in: PubMed
    Score: 0.010
  143. Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998 Mar; 43(2):334-9.
    View in: PubMed
    Score: 0.010
  144. Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord. 2018 03; 33(3):468-472.
    View in: PubMed
    Score: 0.010
  145. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017 12 01; 140(12):3191-3203.
    View in: PubMed
    Score: 0.009
  146. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
    View in: PubMed
    Score: 0.009
  147. Thalamic DBS with a constant-current device in essential tremor: A?controlled clinical trial. Parkinsonism Relat Disord. 2017 Jul; 40:18-26.
    View in: PubMed
    Score: 0.009
  148. Familial essential tremor in 4 kindreds. Prospects for genetic mapping. Arch Neurol. 1997 Mar; 54(3):289-94.
    View in: PubMed
    Score: 0.009
  149. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
    View in: PubMed
    Score: 0.009
  150. [Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997; 58(4):153-62.
    View in: PubMed
    Score: 0.009
  151. Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017 02; 35:75-81.
    View in: PubMed
    Score: 0.009
  152. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996 Dec; 47(6):1435-41.
    View in: PubMed
    Score: 0.009
  153. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
    View in: PubMed
    Score: 0.009
  154. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg. 1996 Aug; 83(2):420-22.
    View in: PubMed
    Score: 0.009
  155. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016 07; 48(7):733-9.
    View in: PubMed
    Score: 0.009
  156. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996 May; 11(3):250-6.
    View in: PubMed
    Score: 0.009
  157. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.008
  158. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996 Jan; 46(1):68-74.
    View in: PubMed
    Score: 0.008
  159. Whole-Exome Sequencing in Familial Parkinson Disease. JAMA Neurol. 2016 Jan; 73(1):68-75.
    View in: PubMed
    Score: 0.008
  160. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.008
  161. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995 Oct; 37(4):680-6; discussion 686-7.
    View in: PubMed
    Score: 0.008
  162. Response and immunoresistance to botulinum toxin injections. Neurology. 1995 Sep; 45(9):1743-6.
    View in: PubMed
    Score: 0.008
  163. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015 Dec; 30(14):1885-92.
    View in: PubMed
    Score: 0.008
  164. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995 Jul; 32(7):516-8.
    View in: PubMed
    Score: 0.008
  165. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.008
  166. A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. J Geriatr Psychiatry Neurol. 2015 Sep; 28(3):210-7.
    View in: PubMed
    Score: 0.008
  167. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015 Jul; 14(7):710-9.
    View in: PubMed
    Score: 0.008
  168. Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995 Apr; 45(4):645-8.
    View in: PubMed
    Score: 0.008
  169. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case report, and assessment of stimulation threshold safety. Neuromodulation. 2014 Jul; 17(5):405-18; discussion 418.
    View in: PubMed
    Score: 0.007
  170. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994 Jun; 44(6):1137-43.
    View in: PubMed
    Score: 0.007
  171. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014 Aug; 29(9):1171-80.
    View in: PubMed
    Score: 0.007
  172. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014 Aug; 85(8):882-4.
    View in: PubMed
    Score: 0.007
  173. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
    View in: PubMed
    Score: 0.007
  174. Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994; 42:189-201.
    View in: PubMed
    Score: 0.007
  175. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):567-72.
    View in: PubMed
    Score: 0.007
  176. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb; 20(2):142-8.
    View in: PubMed
    Score: 0.007
  177. Hereditary motor-sensory neuropathy and movement disorders. Muscle Nerve. 1993 Sep; 16(9):904-10.
    View in: PubMed
    Score: 0.007
  178. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993 Jul; 95(1):38-48.
    View in: PubMed
    Score: 0.007
  179. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993 May; 43(5):937-41.
    View in: PubMed
    Score: 0.007
  180. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993 Apr; 43(4):834-6.
    View in: PubMed
    Score: 0.007
  181. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(?)) injections in blepharospasm. J Neural Transm (Vienna). 2013 Sep; 120(9):1345-53.
    View in: PubMed
    Score: 0.007
  182. Psychogenic myoclonus. Neurology. 1993 Feb; 43(2):349-52.
    View in: PubMed
    Score: 0.007
  183. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
    View in: PubMed
    Score: 0.007
  184. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
    View in: PubMed
    Score: 0.007
  185. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
    View in: PubMed
    Score: 0.007
  186. Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. Eur J Neurol. 2012 Dec; 19(12):1525-31.
    View in: PubMed
    Score: 0.006
  187. Low body weight in Parkinson's disease. South Med J. 1992 Apr; 85(4):351-4.
    View in: PubMed
    Score: 0.006
  188. Acoustic reflex abnormalities in cranial-cervical dystonia. Neurology. 1992 Mar; 42(3 Pt 1):594-7.
    View in: PubMed
    Score: 0.006
  189. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012 Feb; 11(2):140-9.
    View in: PubMed
    Score: 0.006
  190. Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8.
    View in: PubMed
    Score: 0.006
  191. Tardive tremor. Mov Disord. 1992; 7(1):53-7.
    View in: PubMed
    Score: 0.006
  192. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012 Feb; 27(2):284-8.
    View in: PubMed
    Score: 0.006
  193. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991 Dec; 48(12):1253-6.
    View in: PubMed
    Score: 0.006
  194. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.006
  195. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012 Feb 15; 313(1-2):35-41.
    View in: PubMed
    Score: 0.006
  196. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
    View in: PubMed
    Score: 0.006
  197. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.006
  198. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul; 41(7):1088-91.
    View in: PubMed
    Score: 0.006
  199. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol. 2012 Jan; 19(1):121-7.
    View in: PubMed
    Score: 0.006
  200. Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord. 2011 Aug; 17(7):537-42.
    View in: PubMed
    Score: 0.006
  201. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May; 10(5):415-23.
    View in: PubMed
    Score: 0.006
  202. Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord. 2011 Aug 01; 26(9):1729-32.
    View in: PubMed
    Score: 0.006
  203. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011 Apr; 178(4):1509-16.
    View in: PubMed
    Score: 0.006
  204. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011 Jun; 17(5):321-7.
    View in: PubMed
    Score: 0.006
  205. Essential tremor: clinical correlates in 350 patients. Neurology. 1991 Feb; 41(2 ( Pt 1)):234-8.
    View in: PubMed
    Score: 0.006
  206. Orthostatic tremor: an association with essential tremor. Mov Disord. 1991; 6(1):60-4.
    View in: PubMed
    Score: 0.006
  207. CSF A?(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010 Nov 15; 25(15):2682-5.
    View in: PubMed
    Score: 0.006
  208. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.006
  209. LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011 Jan 07; 487(2):174-6.
    View in: PubMed
    Score: 0.006
  210. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.006
  211. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 Jan; 26(1):147-52.
    View in: PubMed
    Score: 0.006
  212. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug; 53(8):633-9.
    View in: PubMed
    Score: 0.006
  213. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010 Aug 09; 480(1):78-82.
    View in: PubMed
    Score: 0.006
  214. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010 May; 31(5):561-8.
    View in: PubMed
    Score: 0.006
  215. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990 May; 83(5):525-32.
    View in: PubMed
    Score: 0.006
  216. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010 Oct; 11(4):401-8.
    View in: PubMed
    Score: 0.006
  217. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
    View in: PubMed
    Score: 0.006
  218. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
    View in: PubMed
    Score: 0.006
  219. Botulinum toxin injections for cervical dystonia. Neurology. 1990 Feb; 40(2):277-80.
    View in: PubMed
    Score: 0.006
  220. Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up. Mov Disord. 2010 Jan 30; 25(2):232-8.
    View in: PubMed
    Score: 0.006
  221. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol. 1990; 53:293-304.
    View in: PubMed
    Score: 0.005
  222. Tardive oculogyric crises. Neurology. 1989 Nov; 39(11):1434-7.
    View in: PubMed
    Score: 0.005
  223. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989 Nov; 149(11):2486-92.
    View in: PubMed
    Score: 0.005
  224. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
    View in: PubMed
    Score: 0.005
  225. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009 Sep; 66(9):1106-13.
    View in: PubMed
    Score: 0.005
  226. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989 Aug; 46(8):862-7.
    View in: PubMed
    Score: 0.005
  227. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
    View in: PubMed
    Score: 0.005
  228. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009 Oct; 10(4):347-53.
    View in: PubMed
    Score: 0.005
  229. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989; 4(4):303-9.
    View in: PubMed
    Score: 0.005
  230. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989; 4(3):249-60.
    View in: PubMed
    Score: 0.005
  231. Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry. 1988 Dec; 51(12):1512-9.
    View in: PubMed
    Score: 0.005
  232. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
    View in: PubMed
    Score: 0.005
  233. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.005
  234. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
    View in: PubMed
    Score: 0.005
  235. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
    View in: PubMed
    Score: 0.005
  236. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009 May; 71(5):551-8.
    View in: PubMed
    Score: 0.005
  237. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008 Apr; 129(4):526-9.
    View in: PubMed
    Score: 0.005
  238. Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology. 1988 Apr; 38(4):522-7.
    View in: PubMed
    Score: 0.005
  239. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008 Feb; 7(2):720-30.
    View in: PubMed
    Score: 0.005
  240. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008; 20(3):357-63.
    View in: PubMed
    Score: 0.005
  241. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988; 49:103-16.
    View in: PubMed
    Score: 0.005
  242. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol. 1988; 49:117-23.
    View in: PubMed
    Score: 0.005
  243. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987 Dec; 10(6):511-21.
    View in: PubMed
    Score: 0.005
  244. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.
    View in: PubMed
    Score: 0.005
  245. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007; 149(9):857-66; discussion 866.
    View in: PubMed
    Score: 0.005
  246. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
    View in: PubMed
    Score: 0.005
  247. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(1):77-80.
    View in: PubMed
    Score: 0.005
  248. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007 Jan 23; 68(4):272-6.
    View in: PubMed
    Score: 0.004
  249. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007 Jan; 22(1):55-61.
    View in: PubMed
    Score: 0.004
  250. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006 Mar; 21(3):306-9.
    View in: PubMed
    Score: 0.004
  251. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006 Mar 14; 66(5):672-7.
    View in: PubMed
    Score: 0.004
  252. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.004
  253. The phenomenology of tics. Mov Disord. 1986; 1(1):17-26.
    View in: PubMed
    Score: 0.004
  254. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
    View in: PubMed
    Score: 0.004
  255. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53.
    View in: PubMed
    Score: 0.004
  256. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
    View in: PubMed
    Score: 0.004
  257. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004 Apr 15; 219(1-2):63-9.
    View in: PubMed
    Score: 0.004
  258. Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci. 2004 Jan 15; 217(1):89-99.
    View in: PubMed
    Score: 0.004
  259. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.004
  260. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003 Oct; 18(10):1190-2.
    View in: PubMed
    Score: 0.004
  261. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.003
  262. Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003 Aug; 4(4):185-9.
    View in: PubMed
    Score: 0.003
  263. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003 Apr 08; 60(7):1189-91.
    View in: PubMed
    Score: 0.003
  264. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003 Jan; 33(1):85-9.
    View in: PubMed
    Score: 0.003
  265. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002 Mar 26; 58(6):881-4.
    View in: PubMed
    Score: 0.003
  266. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.003
  267. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002 Mar; 17(2):339-45.
    View in: PubMed
    Score: 0.003
  268. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
    View in: PubMed
    Score: 0.003
  269. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 2001 Nov 14; 286(18):2245-50.
    View in: PubMed
    Score: 0.003
  270. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001 Nov; 16(6):1137-42.
    View in: PubMed
    Score: 0.003
  271. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001 Jun 01; 305(1):70-2.
    View in: PubMed
    Score: 0.003
  272. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001 Apr; 48(4):818-24; discussion 824-6.
    View in: PubMed
    Score: 0.003
  273. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001 Feb; 58(2):218-22.
    View in: PubMed
    Score: 0.003
  274. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000 Oct 24; 55(8):1218-22.
    View in: PubMed
    Score: 0.003
  275. Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. Brain. 2000 Oct; 123 ( Pt 10):2141-9.
    View in: PubMed
    Score: 0.003
  276. Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 Sep; 69(3):326-36.
    View in: PubMed
    Score: 0.003
  277. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000 Mar 14; 54(5):1195-8.
    View in: PubMed
    Score: 0.003
  278. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.003
  279. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May; 66(5):612-6.
    View in: PubMed
    Score: 0.003
  280. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999 Feb; 56(2):194-200.
    View in: PubMed
    Score: 0.003
  281. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998 Dec; 55(12):1521-3.
    View in: PubMed
    Score: 0.003
  282. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998 Oct; 51(4):1063-9.
    View in: PubMed
    Score: 0.003
  283. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998 Aug; 89(2):194-9.
    View in: PubMed
    Score: 0.002
  284. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
    View in: PubMed
    Score: 0.002
  285. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998 Jan; 50(1):266-70.
    View in: PubMed
    Score: 0.002
  286. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998 Jan; 13(1):150-4.
    View in: PubMed
    Score: 0.002
  287. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997 Nov; 63(5):642-8.
    View in: PubMed
    Score: 0.002
  288. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997 Sep; 87(3):358-67.
    View in: PubMed
    Score: 0.002
  289. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology. 1996 Mar; 46(3):720-6.
    View in: PubMed
    Score: 0.002
  290. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995 Mar; 36(3):501-7; discussion 507-8.
    View in: PubMed
    Score: 0.002
  291. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(4):471-5.
    View in: PubMed
    Score: 0.002
  292. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol. 1994 May; 34(5):466-71.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.